An observational study in Chronic Hepatitis B, sponsored by Ausper Biopharma Co., Ltd.. Recruiting at 37 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Ausper Biopharma Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd. — 8 open to participants now, 11 under way, 1 of them phase 3. Hepatitis B, Chronic · Ausper Biopharma Co., Ltd..
Among the 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd., this one is one of 5 that started in 2025, is the only observational one, reaches primary completion later than 8 of the 10 other live ones, and was the 8th registered.
899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.
Browse Hepatitis B, Chronic studies →8 of the 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 1
First in 2023; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 200 is below the median of 400 across 209 observational studies indexed under Hepatitis B, Chronic.
Median enrollment 110 across the 12 interventional studies, 200 across the 1 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ausper Biopharma Co., Ltd. is the lead sponsor of 14 studies on the registry; 9 are open to participants now.
6 of the studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07246889Phase 3Ausper Biopharma Co., Ltd.Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) | 2026-12-18 |
| NCT07137910Ausper Biopharma Co., Ltd.A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) | 2026-12-12 |
| NCT07884864Ausper Biopharma Co., Ltd.A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants | 2027-04-30 |
| NCT07635186Ausper Biopharma Co., Ltd.A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B | 2027-06-20 |
| NCT07069569Ausper Biopharma Co., Ltd.A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs | 2027-07-15 |
Add all 6 to your calendar (.ics) → With an account.
Among the 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.
Participants who have previously participated in AHB-137 clinical trials
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percentage of participants maintained complete response(defined as HBsAg < 0.05IU/mL and HBV DNA < lower limit of quantification).
Time frame: Up to 80 weeks
Proportion of participants achieving and maintaining HBsAg<0.05 IU/mL.
Time frame: Up to 80 weeks
Time to loss of HBsAg reversion.
Time frame: Up to 80 weeks
Proportion and time of participants meeting certain test indicators after discontinuation of all CHB treatment.
Time frame: Up to 80 weeks
Serum levels of HBsAg, HBV DNA, HBV RNA, HBcrAg, HBsAb,HBeAb.
Time frame: Up to 80 weeks
Changes of the five-level five-dimensional health scale (EQ-5D-5L) instrument in participants compared with baseline.
Time frame: Up to 80 weeks
Percentage of participants with mutations
Time frame: Up to 80 weeks
Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAE), adverse events, hepatic endpoint events, deathsand clinically significant examination results.
Examination including laboratory examination, electrocardiogram (ECG) examination.
Time frame: Up to 80 weeks
Changes of the hepatitis B quality of life (HBQOL) instrument in participants compared with baseline.
Time frame: Up to 80 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jan 2028, 28 months after the start.
Of 72 observational studies under Hepatitis B, Chronic, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 99. This study's planned 28 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.